Bionaut Labs Debuts From Stealth Mode to Accelerate Development of New Precision Treatment Modality for Brain Disorders
Summary
We are extremely pleased to debut with the strong support of this world-class syndicate, to fulfill our mission of helping patients suffering from debilitating brain diseases who lack treatment options.” Bionauts™ can be constructed in different versions with custom geometries and surface characteristics. The Bionaut™ technology opens the door to precise treatment for a wide variety of severe brain disorders,” said Santosh Kesari, M.D., Ph.D., Chair of the Department of Translational Neurosciences, Director of Neuro-Oncology at St. John’s Cancer Institute, and a member of Bionaut Lab’s Advisory Board. What’s even more exciting is that the anatomical targeting capabilities of the Bionaut™ platform make new therapeutic technologies such as antisense, siRNA, gene therapy, CRISPR-Cas9, and oncolytic viruses viable in challenging clinical settings,” added Errol DeSouza, Ph.D., co-founder, Neurocrine Biosciences, and Head of Bionaut Labs’ Advisory Board. Led by a world-class team of medical, engineering, and drug development experts, Bionaut Labs’ headquarters is in Los Angeles, California, with additional R&D sites in Israel and at the Max Planck Institute in Germany. With over fourteen billion dollars under management, the firm focuses on a broad range of areas including consumer, enterprise, ai, fintech and financial services, semiconductors, health, agriculture/food, sustainable energy, and robotics.